New hope to delay prostate cancer progression in chinese men

NCT ID NCT04076059

Ongoing Disease control Sponsor: Astellas Pharma China, Inc. Source: ClinicalTrials.gov ↗

Summary

This study tested whether adding the drug enzalutamide to standard hormone therapy works better than standard therapy alone for Chinese men whose prostate cancer has spread. It involved 180 participants and was designed to see if the combination could delay cancer progression and improve outcomes. The study was randomized and double-blind, meaning neither patients nor doctors knew who received the real drug versus a placebo.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Site CN86001

Guangzhou, China
Site CN86002

Shanghai, China
Site CN86003

Shanghai, China
Site CN86004

Nanchang, China
Site CN86005

Ürümqi, China
Site CN86009

Changsha, China
Site CN86010

Shanghai, China
Site CN86011

Shenzhen, China
Site CN86012

Tianjin, China
Site CN86013

Shanghai, China
Site CN86014

Shanghai, China
Site CN86016

Changsha, China
Site CN86017

Zhengzhou, China
Site CN86019

Wuhan, China
Site CN86020

Shenyang, China
Site CN86021

Wuxi, China
Site CN86022

Beijing, China
Site CN86023

Changsha, China
Site CN86024

Changchun, China
Site CN86025

Fuzhou, China
Site CN86026

Wuhan, China
Site CN86027

Shanghai, China
Site CN86028

Hangzhou, China
Site CN86029

Zhengzhou, China
Site CN86032

Suzhou, China
Site CN86035

Beijing, China
Site CN86036

Hangzhou, China
Site CN86038

Xi'an, China

Conditions

Explore the condition pages connected to this study.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER